CSIMarket Company Name, Ticker, Customers, else..
 
Neximmune Inc   (NEXI)
Other Ticker:  
 
 
Price: $0.2159 $-0.02 -8.167%
Day's High: $0.28 Week Perf: 7.41 %
Day's Low: $ 0.22 30 Day Perf: -39.27 %
Volume (M): 10 52 Wk High: $ 28.69
Volume (M$): $ 2 52 Wk Avg: $3.82
Open: $0.23 52 Wk Low: $0.20



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -21
 Cash Flow (TTM) (Millions $) -14
 Capital Exp. (TTM) (Millions $) 0

Neximmune Inc
Neximmune Inc is a biotechnology company that specializes in developing novel immunotherapies for the treatment of various diseases. The company focuses on next-generation T-cell therapies to harness the power of the immune system to target and eliminate cancer cells. Neximmune's platform technology utilizes the body's natural defense mechanisms to create personalized therapies that are specifically tailored to each patient. By leveraging their expertise in molecular immunology, the company aims to revolutionize the field of immunotherapy and provide innovative treatment options for patients.


   Company Address: 9119 Gaither Road Gaithersburg, 20877 MD
   Company Phone Number: 825-9810   Stock Exchange / Ticker: NEXI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stocks on the Move

Navigating a Divergent Path Nvidias Rise and NexImmunes Struggles in the Stock Market

Published Wed, Aug 7 2024 7:22 PM UTC

The financial markets are often a stage where contrasting fortunes play out in real time, painting a picture of industry trends and investor sentiment. This past month has been particularly telling, exemplified by the stark contrast between two companies: Nvidia and NexImmune.'Nvidia: The AI Titan'On July 29, 2024, Nvidia (NASDAQ: NVDA), the frontline warrior in the artifici...
Neximmune Inc

NexImmune Inc Sees Operating Shortfall Decrease in First Quarter of 2024

Financial News Report: NexImmune, Inc. Shows Positive Signs Amid Revenue Challenges
May 3, 2024 - NexImmune, Inc., a biotechnology company focusing on immunotherapy, has faced challenges in its revenue during the first quarter of 2024 earnings season. Despite these challenges, the company has shown positive signs of improvement, with its operating shortfall decreasing from $9.825409 million in Q1 2023 to $2.757466 million in Q1 2024.
The recent financial reports indicate that NexImmune is making progress towards improving its financial situation. This increase is significant for the company as it continues to unfold its business model and compete effectively in the emerging growth industry.
Financing Agreement

NexImmune's Financial Dilemma: High Leverage Ratio Despite Successful Offerings

Published Tue, Feb 6 2024 9:43 PM UTC


NexImmune's Tangible Leverage Ratio Reaches New All-Time High Despite Borrowings
NexImmune recently announced the closing of a $3.67 million registered direct offering priced at-the-market under Nasdaq rules. This comes at a time when the company's Tangible Leverage Ratio has deteriorated to 0.76 in the third quarter of 2023, reaching a new all-time high.
In com...
Shares

NexImmune's Registered Direct Offering Positions Company for Further Growth and Development

Published Fri, Feb 2 2024 7:00 PM UTC


In an exciting move that reflects the ongoing progress and potential of NexImmune Inc, the company has recently announced a registered direct offering priced at-the-market under Nasdaq rules. The offering, totaling $3.67 million, signifies a significant step forward for NexImmune as it seeks to leverage its innovative immunotherapy platform to address unmet medical need...
Neximmune Inc

Neximmune Inc. Surpasses Industry Expectations as Operating Loss Narrows in Q3 of 2023


As a biotechnology company operating in the Major Pharmaceutical Preparations industry, Neximmune Inc is an emerging player in the field of immunotherapy. While larger companies dominate the headlines, it is important to pay attention to the smaller businesses that are also making significant strides. Recently, Neximmune Inc revealed its financial results for the third quarter of 2023, which portray a promising picture of the company's performance.
One key highlight from the report is that Neximmune Inc reported an operating loss of $-9.995767 million for the third quarter of 2023. While operating losses are never ideal, it is important to note that this figure represents a significant improvement compared to the same period in 2022, where the operating loss stood at $-14.856101 million. This impressive reduction in operating loss showcases the company's dedication to cost optimization and signifies a positive direction for Neximmune Inc.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com